Toward the Prognostic Signi fi cance and Therapeutic Potential of HER 3 Receptor Tyrosine Kinase in Human Colon Cancer

Purpose: Abnormal accumulation and dysregulation of the epidermal growth factor receptor family member HER3 is associated with the development of various human cancers including those of the breast, lung, and ovary. We have previously shown that in melanoma HER3 is frequently overexpressed and is associated with poor prognosis. However, the importance of HER3 in colon cancer and its putative prognostic significance is still unknown. Experimental Design: HER3 expression was analyzed in primary colon tumors from 110 patients by immunohistochemistry and correlated with time of progression. Parallel to this, the influence of HER3 overexpression on cell proliferation, migration, invasion, and apoptosis was investigated in four different colon cancer cell lines including DLD-1, LoVo, CaCO2, and T-84. Results: HER3 was detected at high frequency and exclusively at the membrane of the primary tumors. Elevated HER3 expression levels may serve as a putative prognostic marker because it associates with cell proliferation and decreased time to disease progression. High HER3 protein expression as well as phosphorylation levels were detected in tested cells. HER3 downregulation by RNA interference abrogated cell proliferation, migration, and invasion. In addition, suppression of HER3 resulted in a G2–M cell-cycle arrest, induced apoptosis, and led to morphologic changes in colon cancer cell lines. Furthermore, application of a monoclonal antibody specific to the extracellular portion of the receptor reduced heregulin-b1–induced migration and invasion and also induced apoptosis in colon cancer cell lines. Conclusion:Wepostulate that HER3 is critically involved in colon cancer progression andmay serve as a novel target for therapeutic intervention. Clin Cancer Res; 18(4); 956–68. 2011 AACR.

[1]  Andrew V Kossenkov,et al.  ErbB3 expression promotes tumorigenesis in pancreatic adenocarcinoma , 2010, Cancer biology & therapy.

[2]  A. Jemal,et al.  Cancer Statistics, 2010 , 2010, CA: a cancer journal for clinicians.

[3]  Sujin Choi,et al.  Tephrosin induces internalization and degradation of EGFR and ErbB2 in HT-29 human colon cancer cells. , 2010, Cancer letters.

[4]  Dhara N. Amin,et al.  HER3 Comes of Age: New Insights into Its Functions and Role in Signaling, Tumor Biology, and Cancer Therapy , 2010, Clinical Cancer Research.

[5]  M. Bertagnolli,et al.  Molecular origins of cancer: Molecular basis of colorectal cancer. , 2009, The New England journal of medicine.

[6]  F. Mancini,et al.  HER3 is required for the maintenance of neuregulin‐dependent and ‐independent attributes of malignant progression in prostate cancer cells , 2009, International journal of cancer.

[7]  D. Threadgill,et al.  Tumor-specific apoptosis caused by deletion of the ERBB3 pseudo-kinase in mouse intestinal epithelium. , 2009, The Journal of clinical investigation.

[8]  Dong Xu,et al.  Comparative Study on Overexpression of HER2/neu and HER3 in Gastric Cancer , 2009, World Journal of Surgery.

[9]  G. Guimarães,et al.  ErbB family immunohistochemical expression in colorectal cancer patients with higher risk of recurrence after radical surgery , 2009, International Journal of Colorectal Disease.

[10]  M. Lai,et al.  Colorectal cancer, one entity or three , 2009, Journal of Zhejiang University SCIENCE B.

[11]  H. Kuwano,et al.  Inhibition of Autophagy by 3-MA Enhances the Effect of 5-FU-Induced Apoptosis in Colon Cancer Cells , 2009, Annals of Surgical Oncology.

[12]  B. Manning,et al.  A complex interplay between Akt, TSC2 and the two mTOR complexes. , 2009, Biochemical Society transactions.

[13]  J. Vadgama,et al.  Role of caspases in 5-FU and selenium-induced growth inhibition of colorectal cancer cells. , 2008, Anticancer research.

[14]  Peter J. Wild,et al.  HER3 Is a Determinant for Poor Prognosis in Melanoma , 2008, Clinical Cancer Research.

[15]  A. Papavassiliou,et al.  HER-3 in colorectal tumourigenesis: from mRNA levels through protein status to clinicopathologic relationships. , 2007, European journal of cancer.

[16]  J. Diallo,et al.  Low nuclear ErbB3 predicts biochemical recurrence in patients with prostate cancer , 2007, BJU international.

[17]  K. Shokat,et al.  Escape from HER family tyrosine kinase inhibitor therapy by the kinase inactive HER3 , 2007, Nature.

[18]  A. Ullrich,et al.  ErbB-3 predicts survival in ovarian cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  G. Barton,et al.  Emerging roles of pseudokinases. , 2006, Trends in cell biology.

[20]  A. Ullrich,et al.  Anti‐HER‐3 MAbs inhibit HER‐3‐mediated signaling in breast cancer cell lines resistant to anti‐HER‐2 antibodies , 2005, International journal of cancer.

[21]  M. Mann,et al.  Phosphotyrosine interactome of the ErbB-receptor kinase family , 2005, Molecular systems biology.

[22]  L. Anderson,et al.  Inactivation of ErbB3 by siRNA promotes apoptosis and attenuates growth and invasiveness of human lung adenocarcinoma cell line A549 , 2005, Oncogene.

[23]  A. Ullrich,et al.  Tyrosine phosphorylation of PYK2 mediates heregulin‐induced glioma invasion: Novel heregulin/HER3‐stimulated signaling pathway in glioma , 2005, International journal of cancer.

[24]  Takashi Takahashi,et al.  Cell cycle activation in lung adenocarcinoma cells by the ErbB3/phosphatidylinositol 3-kinase/Akt pathway. , 2003, Carcinogenesis.

[25]  K. Bloom,et al.  The Her-2/neu gene and protein in breast cancer 2003: biomarker and target of therapy. , 2003, The oncologist.

[26]  J. R. Reeves,et al.  Expression of the HER1–4 family of receptor tyrosine kinases in breast cancer , 2003, The Journal of pathology.

[27]  J. Slingerland,et al.  Multiple Roles of the PI3K/PKB (Akt) Pathway in Cell Cycle Progression , 2003, Cell cycle.

[28]  A. Citri,et al.  The deaf and the dumb: the biology of ErbB-2 and ErbB-3. , 2003, Experimental cell research.

[29]  Carlos L. Arteaga,et al.  PKB/Akt mediates cell-cycle progression by phosphorylation of p27Kip1 at threonine 157 and modulation of its cellular localization , 2002, Nature Medicine.

[30]  Alfonso Bellacosa,et al.  Cytoplasmic relocalization and inhibition of the cyclin-dependent kinase inhibitor p27Kip1 by PKB/Akt-mediated phosphorylation in breast cancer , 2002, Nature Medicine.

[31]  H. Nagai,et al.  Extensive methylation of hMLH1 promoter region predominates in proximal colon cancer with microsatellite instability. , 2001, Gastroenterology.

[32]  S. Wexner,et al.  Dukes B Colorectal Cancer: Distinct Genetic Categories and Clinical Outcome Based on Proximal or Distal Tumor Location , 2001 .

[33]  Mark A. Stephenson,et al.  High c-erbB-3 protein expression is associated with shorter survival in advanced non-small cell lung carcinomas. , 1997, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[34]  M. Ilyas,et al.  Genetic pathways in colorectal cancer , 1996, Histopathology.

[35]  A. Ullrich,et al.  Heregulin‐dependent regulation of HER2/neu oncogenic signaling by heterodimerization with HER3. , 1995, The EMBO journal.

[36]  J. DiPaolo,et al.  Refined localization of the erbB-3 proto-oncogene by direct visualization of FISH signals on LUT-inverted and contrast-enhanced digital images of DAPI-banded chromosomes. , 1995, Cancer genetics and cytogenetics.

[37]  H. Kim,et al.  Epidermal growth factor-dependent association of phosphatidylinositol 3-kinase with the erbB3 gene product. , 1994, The Journal of biological chemistry.

[38]  L. Cantley,et al.  Insect cell-expressed p180erbB3 possesses an impaired tyrosine kinase activity. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[39]  L. Cantley,et al.  ErbB3 is involved in activation of phosphatidylinositol 3-kinase by epidermal growth factor , 1994, Molecular and cellular biology.

[40]  W. Gullick,et al.  Identification of c‐erbB‐3 binding sites for phosphatidylinositol 3′‐kinase and SHC using an EGF receptor/c‐erbB‐3 chimera. , 1994, The EMBO journal.

[41]  M. Sliwkowski,et al.  Coexpression of erbB2 and erbB3 proteins reconstitutes a high affinity receptor for heregulin. , 1994, The Journal of biological chemistry.

[42]  L. Cantley,et al.  The erbB3 gene product is a receptor for heregulin. , 1994, The Journal of biological chemistry.

[43]  M. Kraus,et al.  Efficient coupling with phosphatidylinositol 3-kinase, but not phospholipase C gamma or GTPase-activating protein, distinguishes ErbB-3 signaling from that of other ErbB/EGFR family members , 1994, Molecular and cellular biology.

[44]  S N Thibodeau,et al.  Microsatellite instability in cancer of the proximal colon. , 1993, Science.

[45]  L. Cantley,et al.  Oncogenes and signal transduction , 1991, Cell.

[46]  G. Plowman,et al.  Molecular cloning and expression of an additional epidermal growth factor receptor-related gene. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[47]  B. Vogelstein,et al.  A genetic model for colorectal tumorigenesis , 1990, Cell.

[48]  M. Kraus,et al.  Isolation and characterization of ERBB3, a third member of the ERBB/epidermal growth factor receptor family: evidence for overexpression in a subset of human mammary tumors. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[49]  Y Iwamoto,et al.  A rapid in vitro assay for quantitating the invasive potential of tumor cells. , 1987, Cancer research.

[50]  J. Slingerland,et al.  PKB/Akt phosphorylates p27, impairs nuclear import of p27 and opposes p27-mediated G1 arrest , 2002, Nature Medicine.

[51]  K. Pavelić,et al.  Expression of erbB-3 protein in colorectal adenocarcinoma: correlation with poor survival , 2000, Journal of Cancer Research and Clinical Oncology.